Paolo Tarantino (P Tarantino)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 52

Top Topics

Locally Advanced

Positive Breast Cancer

Epidermal Growth Factor Receptor

Top Venues

Nature communications

Current oncology reports

NPJ breast cancer

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Steven Jay Isakoff, Vicente Valero, Meredith Faggen, Therese Marie Mulvey, Ron Bose, Douglas Weckstein, Antonio C Wolff, Katherine E Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P Kelly Marcom, Kathy S Albain, Patricia DeFusco, Nadine M Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar F Rimawi, Vandana G Abramson, Paula R Pohlmann, Catherine H Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Adrienne G Waks, Michelle DeMeo, Harold J Burstein, Ann H Partridge, Patrizia Dell'Orto, Leila Russo, Emma Krause, Daniel J Newhouse, Busem Binboğa Kurt, Elizabeth A Mittendorf, Bryan Paul Schneider, Adrienne G Waks, Eric P Winer, Ian E Krop, Sara M Tolaney, null null, null null
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports (2024)
Adrienne G Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortes, Sara M Tolaney, Aleix Prat
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nature reviews. Clinical oncology (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Eleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
The HER2-low revolution in breast oncology: steps forward and emerging challenges. Therapeutic advances in medical oncology 15 (2023)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Mary Anne Fenton, Paolo Tarantino, Stephanie L Graff
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current oncology (Toronto, Ont.) 30 (12) (2023)
Mary Anne Fenton, Paolo Tarantino, Stephanie L Graff
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current oncology (Toronto, Ont.) 30 (12) (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Chiara Corti, Federica Giugliano, Eleonora Nicolò, Paolo Tarantino, Carmen Criscitiello, Curigliano Giuseppe
HER2-Low Breast Cancer: a New Subtype? Current treatment options in oncology (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Dario Trapani, Qingchun Jin, Caroline C Block, Rachel A Freedman, Nancy U Lin, Paolo Tarantino, Elizabeth A Mittendorf, Tari A King, Susan C Lester, Jane E Brock, Nabihah Tayob, Craig A Bunnell, Sara M Tolaney, Harold J Burstein
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO oncology practice (2023)
Mary Anne Fenton, Paolo Tarantino, Stephanie L Graff
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current oncology (Toronto, Ont.) 30 (12) (2023)
Niraj Neupane, Sangharsha Thapa, Abhinav Bhattarai, Kriti Ahuja, Ilana Schlam, Abhenil Mittal, Sara M Tolaney, Paolo Tarantino
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan. Current oncology reports (2023)
Mary Anne Fenton, Paolo Tarantino, Stephanie L Graff
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current oncology (Toronto, Ont.) 30 (12) (2023)
Paolo Tarantino, Sara M Tolaney
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules. JCO oncology practice (2023)
Eleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
The HER2-low revolution in breast oncology: steps forward and emerging challenges. Therapeutic advances in medical oncology 15 (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Paolo Tarantino, H Gupta, M E Hughes, J Files, S Strauss, G Kirkner, A-M Feeney, Y Li, Ana Christina Garrido-Castro, R Barroso-Sousa, Brittany L Bychkovsky, S DiLascio, Lynette M Sholl, L MacConaill, N Lindeman, B E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, E P Winer, D Dillon, Curigliano Giuseppe, A D Cherniack, Sara M Tolaney, N U Lin
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Mary Anne Fenton, Paolo Tarantino, Stephanie L Graff
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current oncology (Toronto, Ont.) 30 (12) (2023)
Paolo Tarantino, Sara M Tolaney
The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors. Cancer research 82 (20) (2022)
Edoardo Crimini, Matteo Repetto, Paolo Tarantino, Liliana Ascione, Gabriele Antonarelli, Elena Guerini Rocco, Massimo Barberis, Luca Mazzarella, Curigliano Giuseppe
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers 14 (13) (2022)
Paolo Tarantino, Curigliano Giuseppe, Sara M Tolaney
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer discovery 12 (9) (2022)
Ilana Schlam, Paolo Tarantino, Stefania Morganti, Filipa C Lynce, Dario Trapani, Erica L Mayer, Ana Christina Garrido-Castro, Ada Waks, Sara M Tolaney
Emerging Targeted Therapies for Early Breast Cancer. Drugs 82 (14) (2022)
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau T Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C Wolff, Katherine Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, P Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar F Rimawi, Vandana Abramson, Paula R Pohlmann, Catherine H Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Yue Zheng, Shoshana M Rosenberg, Richard D Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann H Partridge, Eric P Winer, Ian E Krop, Sara M Tolaney
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ breast cancer 8 (1) (2022)
Federica Giugliano, Chiara Corti, Paolo Tarantino, Flavia Michelini, Giuseppe Curigliano
Bystander effect of antibody-drug conjugates: fact or fiction? Current oncology reports 24 (7) (2022)
Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A Mittendorf, Hope Rugo, Sara M Tolaney, Giampaolo Bianchini, Fabrice Andre, Curigliano Giuseppe
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ breast cancer 8 (1) (2022)
Paolo Tarantino, Sara M Tolaney, Nadia Harbeck, Javier Cortes, Curigliano Giuseppe
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (32) (2021)
Paolo Tarantino, Stefania Morganti, Curigliano Giuseppe
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of targeted anti-tumor therapy 2 (2) (2021)
Pamela Trillo Aliaga, Dario Trapani, José Luis Sandoval, Edoardo Crimini, Gabriele Antonarelli, Grazia Vivanet, Stefania Morganti, Chiara Corti, Paolo Tarantino, Alex Friedlaender, Carmen Belli, Ida Minchella, Marzia Locatelli, Angela Esposito, Carmen Criscitiello, Curigliano Giuseppe
Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers 13 (22) (2021)
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Curigliano Giuseppe
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel, Switzerland) 14 (9) (2021)
Paolo Tarantino, Dario Trapani, Curigliano Giuseppe
Mastering the Use of Novel Anti-HER2 Treatment Options. JCO oncology practice 17 (10) (2021)